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Abstract
Background: One of the greatest challenges facing biomedical research is the integration and
sharing of vast amounts of information, not only for individual researchers, but also for the
community at large. Agent Based Modeling (ABM) can provide a means of addressing this challenge
via a unifying translational architecture for dynamic knowledge representation. This paper presents
a series of linked ABMs representing multiple levels of biological organization. They are intended
to translate the knowledge derived from in vitro models of acute inflammation to clinically relevant
phenomenon such as multiple organ failure.
Results and Discussion: ABM development followed a sequence starting with relatively direct
translation from in-vitro derived rules into a cell-as-agent level ABM, leading on to concatenated
ABMs into multi-tissue models, eventually resulting in topologically linked aggregate multi-tissue
ABMs modeling organ-organ crosstalk. As an underlying design principle organs were considered
to be functionally composed of an epithelial surface, which determined organ integrity, and an
endothelial/blood interface, representing the reaction surface for the initiation and propagation of
inflammation. The development of the epithelial ABM derived from an in-vitro model of gut
epithelial permeability is described. Next, the epithelial ABM was concatenated with the
endothelial/inflammatory cell ABM to produce an organ model of the gut. This model was validated
against in-vivo models of the inflammatory response of the gut to ischemia. Finally, the gut ABM
was linked to a similarly constructed pulmonary ABM to simulate the gut-pulmonary axis in the
pathogenesis of multiple organ failure. The behavior of this model was validated against in-vivo and
clinical observations on the cross-talk between these two organ systems
Conclusion: A series of ABMs are presented extending from the level of intracellular mechanism
to clinically observed behavior in the intensive care setting. The ABMs all utilize cell-level agents
that encapsulate specific mechanistic knowledge extracted from in vitro experiments. The
execution of the ABMs results in a dynamic representation of the multi-scale conceptual models
derived from those experiments. These models represent a qualitative means of integrating basic
scientific information on acute inflammation in a multi-scale, modular architecture as a means of
conceptual model verification that can potentially be used to concatenate, communicate and
advance community-wide knowledge.
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Background
The translational challenge arising from the multiple 
scales of biological organization
The sheer volume of biomedical research threatens to
overwhelm the capacity of individuals to process this
information effectively, a situation recognized by the
National Institutes of Health Roadmap in its "New Path-
ways" statement with its call for advancing integrative and
multi-disciplinary research. Effective translational meth-
odologies for knowledge representation need to move
both "vertically" from the bench to the bedside, and be
able to link "horizontally" across multiple researchers
focused on different diseases. The hierarchical structure of
biological systems is well recognized. Information is gen-
erated by research endeavors at multiple scales and hierar-
chies of organization: gene => protein/enzyme => cell =>
tissue => organ => organism. The existence of these hier-
archies presents significant challenges for the translation
of mechanistic research results from one organizational
level to another (see Figures 1). The mirroring of these
multiple levels in the organization of biomedical research
has led to a disparate and compartmentalized community
and resulting organization of data. The consequences of
this are seen primarily in attempts to develop effective
therapies for diseases resulting from disorders of internal
regulatory processes. Examples of such diseases are cancer,
autoimmune disorders and sepsis, all of which demon-
strate complex, non-linear behavior. In particular, there
has been growing interest in the study of inflammation as
a common underlying mechanism in disease processes
ranging from sepsis to atherosclerosis (as noted by the
recent addition of inflammation as an Emphasis Area to
the NIH Roadmap for Medical Research). The investiga-
tion of such a ubiquitous process presents significant chal-
lenges in the integration and concatenation of research
efforts in both the "vertical" and "horizontal" directions.
A possible solution: dynamic knowledge representation via 
agent-based modeling
Mathematical modeling and computer simulation offer a
translational method for achieving this goal. More specif-
ically, computer modeling can be seen as a means of
dynamic knowledge representation that can form a basis
for formal means of testing, evaluating and comparing
what is currently known within the research community.
In this context, the use of computational models is con-
sidered a means of "conceptual model verification," in
which mental or conceptual models generated by
researchers from their understanding of the literature, and
used to guide their research, are "brought to life" such that
their behavioral consequences can be evaluated. I propose
that this use for computational models can be accom-
plished with relatively coarse-grained qualitative models.
The justification for this belief is the fact that biological
systems are generally robust. They function within a wide
range of conditions, yet retain, for the most part, a great
degree of stability with respect to form and function. A
great reliance on minute specific parameters, particularly
given the limitations of the capability for measurement,
would connote a degree of "brittle-ness" in biological sys-
tems that is not substantiated by general observation. Fur-
thermore, there are perpetual and unavoidable
Abstract demonstration of the expansion of information resulting from reductionist investigation of multi-scale biological sys- tems Figure 1
Abstract demonstration of the expansion of information resulting from reductionist investigation of multi-
scale biological systems. Figure 1a shows the highest level of clinically observed phenomenon at the organ level. Figure 1b 
demonstrates graphically the mechanistic knowledge that organ function results from the interactions of multiple cells and 
types of cells. Figure 1c illustrates what a conceptual mechanistic model would look like when a further finer grained level of 
resolution is used. Figure 1c represents where the overwhelming bulk of biomedical research is currently being conducted, 
particularly with respect to the search for drug candidates and mechanisms of disease. Note that the "indistinctness" of Figure 
1c is intentional: attempts to "zoom in" on the Figure may increase local clarity, but at the cost of being able to see the range of 
potential consequences to a particular manipulation.Theoretical Biology and Medical Modelling 2008, 5:11 http://www.tbiomed.com/content/5/1/11
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limitations with respect to the comprehensiveness with
which a system can be quantitatively described; there will
always be a degree of "incompleteness" in the knowledge
of a biological system. Therefore, conceptual models will
always be, to some degree, qualitative, and this fact
should not preclude the use of computational methods to
improve upon the current methods of representing (via
graphs, diagrams and flow charts) and testing of these
models.
Agent Based Modeling (ABM) is a computational mode-
ling technique that is object-oriented, rule-based, discrete-
event and discrete-time. ABM has characteristics that
make it well suited for the goal of dynamic knowledge
representation and conceptual model verification. The
structure of ABM facilitates the development of aggregated
modular multi-scale models [1,2]. ABM are based on the
rules and interactions between the components of a sys-
tem, simulating them in a "virtual world" to create an in-
silico experimental model [3-7]. ABMs have been used to
study biomedical processes such as sepsis [5,6], cancer
[2,8], inflammatory cell trafficking [9] and wound healing
[10]. They have an intrinsically modular structure via the
grouping of components ("agents") into classes based on
similar rules. ABM rules are often expressed as conditional
statements ("if-then" statements), making ABM suited to
expressing the hypotheses that are generated from basic
scientific research. Individual agents "encapsulate" mech-
anistic knowledge in the form of a set of rules concerning
a particular component. The importance of this "encapsu-
lation" in ABM (as opposed to the "compressed" repre-
sentation of knowledge with a mathematical formula,
such as a biochemical rate law) is the placement of the
mechanistic knowledge within a compartmentalized
object. Furthermore, ABM goes beyond the mere instanti-
ation of this knowledge as a single case by concurrently
generating multiple instances of a particular "encapsula-
tion/object." Because of this property, ABM is an expan-
sion of mere rule-based and object-oriented methods.
Multiple individual instances have differing initial condi-
tions by virtue of existing in a heterogeneous environ-
ment. Because stochastic components are embedded in
their rule systems (a well recognized property of biologi-
cal objects [11-13]), individual agents have differing
behavioral trajectories as the ABM is executed. This results
in population-level dynamics derived from the generation
of these multiple trajectories, population dynamics that,
when viewed in aggregate, form the nested, multi-scalar/
hierarchical organization of biological systems. In this
fashion, ABM performs the trans-hierarchical function
desired in an integrative modeling framework (Figure 2).
Multiple scales of Biological Organization, Biomedical Research and Multi-scale ABM Architecture Figure 2
Multiple scales of Biological Organization, Biomedical Research and Multi-scale ABM Architecture. Representa-
tion of the multiple scales of biological organization and the ABM architecture in a nested fashion, to reflect the reliance of the 
higher scale behavior on the mechanisms operating at the lower levels. Of note, the biomedical research community structure 
in the middle is not so represented, to reflect the relative compartmentalization of the community with respect to the opera-
tional aspect of research, though obviously lower scale knowledge and information does influence the hypotheses generated 
and being tested at the higher scale.Theoretical Biology and Medical Modelling 2008, 5:11 http://www.tbiomed.com/content/5/1/11
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ABM, however, is not without its limitations. Specifically,
two major limitations affect its use as a multi-scale mode-
ling platform. The first has to do with the "black box"
quality of ABM. Since the models rely on an ill-defined
principle of "emergence" in order to transcend the episte-
mological boundaries represented by the multiple hierar-
chies of system organization, their behavior is difficult to
characterize analytically. Therefore, ABMs are not "math-
ematical models" per se, being able to be subjected to for-
mal analysis and "solved." Rather, the use of ABM falls
into the category of "simulation science," in which com-
putational analogs of real world systems are produced and
used in a fashion similar to traditional experimental prep-
arations. As such, the sizes of the models, in terms of
numbers of components and scope of their environment,
must have the extensibility at least to approach the dimen-
sions of their real-world reference systems, particularly
when multi-scale phenomena are the goal. Analytical
tasks such as parameter sensitivity analysis and behavior-
space determination rely upon brute force computation to
generate data sets dense enough for appropriately grained
statistical analysis. This requirement leads to the second
hurdle in the use of ABM in a multi-scale context: their rel-
atively high computational requirements as compared to
equation based models. Currently, in general, most ABM
platforms run as emulated parallel processing systems
based on a single threaded central processing unit. The
execution of an ABM requires multiple iterated computa-
tions as each discrete event is carried out, many more than
for equation-based simulations, resulting in significantly
greater computational demands. Despite ongoing work
on hardware and software configurations to increase the
computational efficiency of running ABMs, currently
computational costs constrain the size of feasible ABM
implementation. There is ongoing work in the develop-
ment of "hybrid" model systems intending to use equa-
tions to model those aspects of a system in which mean-
field approximations are valid, and link these compo-
nents to ABMs where spatial heterogeneity and it effects
are significant [14,15]. Additionally, methods are being
developed to algorithmically increase the efficiency of the
evaluation and analysis of complex multi-scale models
[15]. This topic will be explored further in the Discussion.
These challenges notwithstanding, a modular multi-scale
architecture using the agent-based paradigm is proposed
in this paper. I believe the benefits of an agent-based
architecture in terms of modularity, translational efficacy
and structural/organization mapping to biological sys-
tems outweigh the current limitations of this technique.
Furthermore, the case will be made that, in terms of effec-
tive knowledge representation, a qualitative approach
may often suffice for the goal of conceptual model verifi-
cation. Acute inflammation, as a ubiquitous multi-facto-
rial example of biocomplexity, is used as the
demonstration platform for a series of ABMs developed at
multiple levels of resolution, extending from intracellular
signaling leading up to simulated organ function and
organ-organ interactions. Specifically, the model refer-
ence system is the clinical manifestation of multi-scale
disordered acute inflammation, termed systemic inflam-
matory response syndrome (SIRS), multiple organ failure
(MOF) and/or sepsis. These clinical entities form a contin-
uum of disseminated disordered inflammation in
response to severe levels of injury and/or infection, and
represent one of the greatest clinical challenges in the cur-
rent health care environment. The core of agent-based
architecture is a "middle-out" approach that focuses on
representing and modeling cellular behavior as the agent
level. Cells form a natural choice for the agent level in an
ABM architecture. Cells are categorized by type, based on
discovered and hypothesized rules of behavior, and can,
to a great degree, be treated as "input-output" devices act-
ing within a local environment. Cells are structurally and
functionally aggregated into tissues and organs, the over-
all behaviors of which are determined by the actions and
interactions of their constituent cells. Furthermore, the
bulk of ongoing biomedical research is aimed at affecting
the behavior of specific cellular types by the manipulation
of their internal rules, and it is exactly the translation of
this type of information/knowledge beyond the realm of
solitary cells that underlies the core need for a multi-scale
modeling platform.
Therefore, the initial design aspects of a multi-scale archi-
tecture for modeling acute inflammation hinge upon
identifying the key actors involved, and determining exist-
ing hypotheses aimed at unifying the problem of dissem-
inated disordered inflammation. Two such unifying
hypotheses involve viewing disordered systemic inflam-
mation as either a disease of the endothelium [16-18] or
a disease of epithelial barrier function [19]. The former
paradigm points to the endothelial surface as the primary
communication and interaction surface between the
body's tissues and the blood, which carries inflammatory
cells and mediators. Factors supporting this view are the
fact that endothelial activation is a necessary aspect of the
initiation and propagation of inflammation, particularly
in the expansion of local inflammation to systemic
inflammation, and that the histological and functional
consequences of inflammation are extremely pronounced
at the endothelial surface [17]. On the other hand, there
is also compelling evidence that organ dysfunction related
to inflammation is primarily manifest in a failure of epi-
thelial barrier function. Pulmonary, enteric, hepatic and
renal organ systems all display epithelial barrier dysfunc-
tion that has consequences at the macro-organ level
(impaired gas exchange in the lung, loss of immunologi-
cal competence in the gut, decreased synthetic function in
the liver and impaired clearance and resorptive capacity inTheoretical Biology and Medical Modelling 2008, 5:11 http://www.tbiomed.com/content/5/1/11
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the kidney) [19]. The multi-scale architecture presented
herein attempts to reconcile these two hypotheses by con-
catenating their effects within the design of the architec-
ture: there is an epithelial barrier component that is used
to represent the consequence of individual organ failure,
and an endothelial/inflammatory cell component that
provides the "binding" interaction space that generates,
communicates and propagates the inflammatory
response. The primary cell classes in this architecture are
endothelial cells, blood borne inflammatory cells (with
their attendant sub-types) and epithelial cells. The devel-
opment outlined herein will progress start from ABMs
representing the basic cell systems with essentially linear
knowledge translation from basic science experimental
data. The next step proceeds in a more abstract and quali-
tative fashion, extending to tissue/organ level ABMs that
combine the constituent cell system models. It is at this
step that the tissue/organ ABM becomes a dynamic instan-
tiation of the epithelial-endothelial hypothesis men-
tioned above. The abstraction of the model centers on
representing the "active" components involved in that
hypothesis. The model will be validated by comparing its
behavior to that of in-vivo organ-directed experiments
using the established pattern oriented method described
by Grimm et al. [20]. This method centers on the compar-
ison, at multiple levels ranging from constituent rules to
various observed phenomenological behaviors, between
the model and the real-world reference system. Finally,
the next level of biological organization will be repre-
sented by a multi-organ ABM that simulates the organ-
level crosstalk seen in clinical situations. This model will
be an abstract instantiation of the hypothesis linking the
gut to the lung in the pathophysiology of MOF [21-23].
The qualitative nature of the latter two model levels is
acknowledged. However, I wish to note that these models
are presented as the initial manifestations of an evolvable
multi-scale modeling architecture, a "blueprint" of a mod-
eling framework that will be built upon in the future. Fur-
thermore, despite the qualitative nature of the "scale-up"
translation in these models, they do capture and instanti-
ate the "essence" of specific pathophysiological hypothe-
ses. The test of plausibility of these hypotheses (and note,
the focus is on plausibility, not proof) can be examined
through the behavior of these models and matching them
to observations of equivalent scale experimental/clinical
phenomena.
Methods
Development of the basic cell ABMs
The base endothelial/inflammatory cell ABM has been
previously developed and described [5,6]. The following
section will describe the development of the epithelial
barrier model (epithelial barrier agent based model =
EBABM). This development focuses on translating partic-
ular molecular pathways in a particular cell type: tight
junction protein metabolism and pro-inflammatory sign-
aling as pertaining to gut epithelial barrier function seen
in the enterocyte component of the gut. Calibration and
validation follow the established pattern oriented method
well described for ABM [5,6,20] and consist of comparing
the behavior of the model with in vitro reference model
data.
Reference model for the EBABM and validation 
experiments
The reference model for the EBABM is a well-described
human cultured enterocyte model (Caco-2) and its
responses to inflammatory mediators including nitric
oxide (NO) and a pro-inflammatory cytokine mix
("cytomix") that includes tumor necrosis factor (TNF),
interleukin-1 (IL-1) and interferon-gamma (IFN-gamma)
[24-26]. These papers suggest that enterocyte tight junc-
tion (TJ) proteins are involved in the integrity of gut epi-
thelial barrier function, and that the production and
localization of TJ proteins are impaired in a pro-inflam-
matory cytokine milieu. The TJ proteins that seem to be
most affected in this situation are occludin, claudin-1,
ZO-1 and ZO-3. The primary mechanism proposed is the
activation of nuclear factor kappa-B (NF-kappa-B) by pro-
inflammatory cytokines leading to subsequent activation
and production of inducible nitric oxide synthetase
(iNOS). The nitric oxide (NO) produced inhibits synthe-
sis of occludin, ZO-1 and ZO-3 while increasing produc-
tion of claudin-1. Furthermore, the NO impairs
localization of synthesized occludin, claudin-1 and ZO-1
to the cell surface. This effect appears to be due to the
interference of NO with N-ethylmaleimide-sensitive fac-
tor (NSF), a molecule needed for localization of TJ pro-
teins to the cell membrane [27]. These effects are seen
both with administration of exogenous NO, and through
intrinsic production via the cytomix-NF-kappa-B-iNOS
pathway. These papers go on to investigate the effects of
certain blocking agents. Addition of a NO scavenger [26]
eliminates the effects of exogenous NO and cytomix.
Administration of ethyl pyruvate [24] and nicotinamide
adenine dinucleotide (NAD+) [25] both thought to
inhibit NF-kappa-B, also both attenuate the effects of
cytomix. Data points for levels of NO, TJ protein expres-
sion and permeability were at 12, 24 and 48 hours in all
the experiments. Figure 3 is a graphical representation of
the general control logic underlying the agent rule systems
based on the knowledge extracted from [24-27].
EBABM: construction and calibration
The EBABM was constructed using the freeware software
toolkit Netlogo [28]. The architecture and rule systems for
the ABM were constructed using the information gleaned
from the papers listed above. The procedure for develop-
ing ABMs in the context of medical research has beenTheoretical Biology and Medical Modelling 2008, 5:11 http://www.tbiomed.com/content/5/1/11
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extensively described [5,6] and critical points of develop-
ment and structure will be summarized here.
The topology of the EBABM is a 2-dimensional square
grid. The grid has 21 × 21 cells, in each of which there is
an epithelial cell agent ("epi-cell'). The size of this grid
was chosen as a representative portion of a total cell cul-
ture surface for reasons of computational efficiency; the
processes being modeled by the EBABM are proportional
to the cell surface area and the model could be, if desired,
scaled up to any size. There are also two additional simu-
lation "spaces," one layer representing the apical extracel-
lular space (from which the diffusate originates) and
another layer representing the basal extracellular space
(into which the diffusate flows if there is permeability fail-
ure). A screenshot of the EBABM during an experimental
run can be seen in Figure 4. Each epi-cell has 8 immediate
neighbors, and at each contact point there is a simulated
tight junction (TJ). The integrity of the TJ requires both
apposed epi-cells to have adequate production and local-
ization of TJ proteins. The epi-cell agent class contains var-
iables that represent the precursors, cytoplasmic levels
and cell membrane levels of the TJ proteins, as well as
intracellular levels of activated NF-kappa-B and iNOS
mRNA. Furthermore, there are "milieu" variables that rep-
resent NO, cytomix and the diffusate. Algorithmic com-
mands were written for the synthesis of TJ proteins as well
as the pathway for NO induction. Since ABM is a discrete
event computational method, the updating of variables
occurs via multiple iterations as the model is executed.
Therefore there are no kinetic equations per se for the met-
abolic pathways modeled by the agent rules. Rather, the
metabolic rules consist of a simple arithmetical relation-
ship based on the prior state (value) of a particular varia-
ble used to calculate the current value. The specifics of the
algebraic relationship (such as constant values) are tuned
during the calibration process by comparing the values
over time of the simulation variables against the reference
data sets. While this method lacks the "precision" of for-
mally measured and characterized kinetic rate equations,
several factors support its use in this context. First are the
purely pragmatic reasons; detailed metabolic kinetic data
are difficult to obtain, do not exist for vast majority of
metabolic processes (such as TJ protein metabolism), and
even if obtained using ex vitro methods, may not reflect
the kinetics present in an intracellular environment [29].
Additionally, we return to the concept of cells as robust
dynamic objects, in which qualitative scaling of intracel-
lular processes may actually be more than sufficient given
the stochasticity observed in their dynamics [30]
Calibration of the model was done using three behavior
patterns of the EBABM compared to observed phenomena
in the reference experimental systems. The first calibration
was for the basal diffusion rate. The diffusion coefficient
in the unperturbed system was adjusted to match the rate
of diffusion in the reference data set at times 12, 24 and
48 hours. This established the baseline control permeabil-
ity. The second calibration was done to reproduce the lev-
els of administered cytomix and NO. The reference data
sets were the levels of measured NO in both the exoge-
nous NO donor arm and the cytomix administration arm
(as seen in Figure 1 from Ref [26]). Calibration occurred
by modifying the coefficients of the NO induction path-
way algorithm. The third calibration was done with
respect to the TJ protein synthesis/breakdown algorithms.
Steady state TJ protein levels were established using the
inhibition data extrapolated from the Western Blot results
from Ref [26]. For the purposes of this model, at this point
in development of methods for model construction, cali-
brations in this section were done by hand, using trial and
error. It is expected that in the future automated calibra-
tion algorithms would need to be developed in order to
scale up this methodology to more extensive and detailed
models.
Following these three levels of calibration the baseline
EBABM was established. Note that this includes the
EBABM perturbed with both NO and cytomix. No further
modifications were done to the internal metabolism algo-
rithms of the epi-cell class; the only additions were the
Graphical Representation of the control logic extracted from  the basic science references [24, 26, 27]on Gut Epithelial  Barrier Function Figure 3
Graphical Representation of the control logic 
extracted from the basic science references [24, 26, 
27]on Gut Epithelial Barrier Function. General flow-
chart of the components and mechanisms of TJ protein syn-
thesis and localization, the effects of pro-inflammatory 
stimulation, and the effects of interventions with ethyl pyru-
vate and NAD+. All labeled boxes correspond to agent or 
environment state variables within the EBABM. In the actual 
code of the EBABM there are distinct pathways for the dif-
ferent TJ proteins (not shown here for clarity purposes).Theoretical Biology and Medical Modelling 2008, 5:11 http://www.tbiomed.com/content/5/1/11
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presumptive metabolic effects of ethyl pyruvate and NAD+
in the simulated experiments from Figure 6 from Ref [24]
and Figure 2 from Ref [25], respectively.
EBABM: simulations and results
There were three simulated interventions to the baseline
EBABM: 1) addition of a NO scavenger [26], 2) addition
of ethyl pyruvate [24], and 3) addition of NAD+ [25]. The
NO scavenger was simply modeled by reducing the level
of the NO milieu variable after production. Both NAD+
and ethyl pyruvate were modeled using their presumptive
mechanisms of NF-kappa-B inhibition [25,31] by their
insertion as negative influences in the NO induction path-
way algorithm. In-silico experiments were run using these
interventions with data points at 12, 24 and 48 hours as
per the reference papers. Data collection looked at perme-
ability reflecting TJ integrity, levels of TJ proteins and
localization of TJ proteins.
The results of the in-silico runs of the EBABM can be seen
in Figures 5, 6, 7, 8 and 9. Note that the values of the in-
silico experiments are unit-less, but the results qualita-
Screen shot of the Graphical User Interface of the EBABM Figure 4
Screen shot of the Graphical User Interface of the EBABM. Control buttons are on the Left; Graphical Output of the 
simulation is in the center. Graphs of variables corresponding to levels of mediators and tight junction proteins are at the bot-
tom and right. In the Graphical Output Caco-2 agents are seen as pink squares, those with intact Tight Junctions bordered in 
yellow (Letter A), those with failed Tight Junctions bordered in black (Letter B). This particular run is with the addition of 
cytomix (Letter C), seen after 12 hours of incubation (Letter D). The heterogeneous pattern of tight junction failure can be 
seen in the Graphical Output. Levels of Caco-2 iNOS activation can be seen in Graph Letter E, and produced Nitric Oxide 
(NO) can be seen in Graph Letter F. Of note, the total amount of tight junction protein occludin does decrease slightly (Graph 
Letter G), but the amount of occludin localized in the cell membrane drops much more rapidly (Graph Letter H), reflecting the 
impairment of occludin transport due to NO interference with NSF and subsequent loss of tight junction integrity.Theoretical Biology and Medical Modelling 2008, 5:11 http://www.tbiomed.com/content/5/1/11
Page 8 of 20
(page number not for citation purposes)
tively mirror the reference data set. Calibration results can
be seen in Figures 5 and 6. Both of these figures include
runs with exogenous NO, cytomix and cytomix in the
presence of a NO scavenger. Figure 5 demonstrates the cal-
ibrated levels of NO production, while Figure 6 demon-
strates the permeability calibration results. These figures
essentially reproduce the data generated in Ref [26].
The effects of the interventions represent the validation
step in the evaluation of the EBABM. Figure 7 demon-
strates the effects of ethyl pyruvate and NAD+ on permea-
bility, with the data in Figure 6 representing the control
arm. The reference data for the effect of these interven-
tions on the permeability changes with cytomix adminis-
tration can be seen in Figure 1 from Ref [24] with ethyl
pyruvate at 1.0 mM dose, and Figure 1a from Ref [25] with
NAD+ at 0.1 mM dose. Figures 8 and 9 reproduce the
results seen extrapolated from the Western Blot data on
the effect of ethyl pyruvate and NAD+ administration on
TJ proteins, specifically ZO-1 and occludin (Figure 6 from
Ref [24] and Figure 2 from Ref [25]). ZO-1 is significantly
decreased at 48 hours, while occludin starts to drop at 24
hrs with the cytomix and continues to decrease at 48 hrs,
but has a profile more similar to ZO-1 when run with the
exogenous NO only. The simulation of adding both ethyl
pyruvate and NAD+ both obviated the effects of both
exogenous NO and cytomix on both ZO-1 and occludin.
Development of the organ level ABMs
As discussed above, the next level of ABM development is
intended to simulate organs as a concatenation of two dis-
tinct hypotheses of disseminated inflammation and organ
failure: that of endothelial dysfunction and that of epithe-
lial dysfunction. Therefore the structure of these models
involves the 3-dimensional linkage of the cellular surface
ABMs already developed representing these two systems.
The result is a "bilayer" organ model (see Figures 10).
With this abstraction many organ systems can be func-
tionally and morphologically represented. "Hollow" or
"luminal" organs are those that present an epithelialized
surface to the external environment, while retaining an
"internal" intercommunication surface via a blood capil-
lary interface. Examples of such organ systems would be
the lungs, the gut, the kidney, the liver and (topologically)
the skin. While there would obviously be differences
between the functions of the various epithelial cells
depending upon their organ of residence, to a great degree
the central goal of maintaining the "integrity of self" is
Simulated Nitrogen Oxide (NO) Production and response to  NO Scavenger Figure 5
Simulated Nitrogen Oxide (NO) Production and 
response to NO Scavenger. Calibration data is seen in 
the black bars (= Cytomix) and the beige bars (= NO) with 
respect to simulation rules for NO production. The NO data 
match the levels of exogenous NO added in the experiments 
from [26]) in order to establish baseline responses of the epi-
cell agent's TJ protein synthesis/localization algorithms and 
link them to the permeability data seen in the corresponding 
bars in Figure 5. The Cytomix bars in this Figure 4 are used 
to calibrate the iNOS-NO production algorithms within the 
epi-cell agents. The middle data set (grey bars = Cytomix + 
NO scavenger) show the effect of exogenous NO reduction/
elimination on the generated levels of NO in the face of 
Cytomix. This graph can be compared to the upper panel of 
Figure 1 in Ref [26].
Simulated Permeability to NO, Cytomix and Cytomix + NO  scavenger Figure 6
Simulated Permeability to NO, Cytomix and 
Cytomix + NO scavenger. Graph of calibration data of 
the permeability effects of NO and Cytomix, representing 
the diffusion rate through a failed epithelial barrier and the 
effect of NO on the algorithms for epi-cell TJ protein synthe-
sis/localization. As with Figure 4, the black bars (= Cytomix) 
and beige bars (= Exogenous NO) are the calibration arms. 
This graph can be compared with the lower panel of Figure 1 
in Ref [26].Theoretical Biology and Medical Modelling 2008, 5:11 http://www.tbiomed.com/content/5/1/11
Page 9 of 20
(page number not for citation purposes)
done through sustaining epithelial barrier function via the
ubiquitous mechanism of tight-junction integrity [19].
Reference model for the organ ABM: in vivo models of gut 
ischemia and inflammation
In vivo models that examine the inflammatory behavior
of the gut either look at a local effect from direct occlusion
of gut arterial flow [21,32,33] or as a result of some sys-
temic insult, be it hemorrhagic shock [34-36], endotoxin
administration [37,38] or burn injury [39,40]. These stud-
ies suggest that the primary process that initiates inflam-
mation in the gut is ischemia and reperfusion, and the
subsequent effects on the endothelial surfaces within the
gut. The measurable outputs of the reference models exist
at different scales. At the cellular level, tight junction
integrity and epithelial barrier function is one measured
endpoint [41,42], however the organ as a whole also has
an output: the nature of the mesenteric lymph. Multiple
studies suggest that ischemia to the gut (and subsequent
inflammation) leads to the excretion of an as-of-yet uni-
dentified substance in the mesenteric lymph that has pro-
inflammatory qualities. Some characteristics of the sub-
stance can be identified from the literature: it is an acellu-
lar, aqueous substance [43], is greater than 100 kD in size
[44], does not correspond to any currently recognized
cytokine, and is bound or inactivated by albumin [45].
The time course of the production of the substance is
identified to some degree [35,46] but it is unclear if it
arises from a late production of inflamed cells, or is a
product of cellular degeneration or apoptosis, or is a tran-
sudated bacterial product from the intestinal lumen. The
uncertainty with respect to an identified mediator pro-
vides a good example of how the ABM architecture deals
with incomplete knowledge. Based on the characteristics
defined above, we make a hypothesis regarding this sub-
stance with respect to its origin, but acknowledge that this
is, to a great degree, a "best guess." Doing so establishes a
"knowledge bifurcation point," allowing the develop-
ment of potential experiments and/or data that would
"nullify" the particular hypotheses. A specific example
will be demonstrated below.
Organ ABM: construction
Both the original endothelial/inflammatory cell ABM and
the EBABM were developed as 2-dimensional models. In
order to create the bilayer topology of the organ ABM it
was necessary to convert both of these models to the 3-
dimensional version of Netlogo, with each model repre-
sented as a layer of agents projected in the XY plane. The
two layers were then juxtaposed, the endothelial layer
below and the epithelial layer above along the Z-axis. The
simulated blood vessel luminal space occupied another
XY plane one place inferior to the endothelial surface
along the Z-axis. Inflammatory cells move only in this
plane. The organ luminal space occupied the XY plane at
Simulated Permeability Effects of Ethyl Pyruvate and NAD+ Figure 7
Simulated Permeability Effects of Ethyl Pyruvate and 
NAD+. Graph demonstrating the effects of simulated addi-
tion of ethyl pyruvate and NAD+ on the pro-inflammatory 
algorithms within the epi-cell agents. Both of these sub-
stances interfere with NF-kappa-B localization, and therefore 
are "upstream" from the iNOS-NO pathways as represented 
in those rules. This graph can be compared to Figure 1 from 
Ref [24] with ethyl pyruvate at 1.0 mM dose, and Figure 1a 
from Ref [25] with NAD+ at 0.1 mM dose.
Simulated Levels of ZO-1 Expression Figure 8
Simulated Levels of ZO-1 Expression. Graph demon-
strating the levels of simulated ZO-1 expression in control, 
exogenous NO, Cytomix, Cytomix with NO scavenger, 
Cytomix with ethyl pyruvate and Cytomix with NAD+ at 12 
h, 24 h and 48 h. Compare with Figure 6 from Ref [24] and 
Figure 2 from Ref [25] (latter is extrapolated from Western 
blot analysis).Theoretical Biology and Medical Modelling 2008, 5:11 http://www.tbiomed.com/content/5/1/11
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one place superior to the epithelial axis along the Z-axis.
This space contains the "diffusate" that leaks into the gut
in cases of epithelial tight junction failure. For a screen-
shots demonstrating the topology of this model see Fig-
ures 10.
The nature of the initial perturbation was altered to match
that seen in the reference experiments, i.e. tissue ischemia.
With the premise that the inflammatory response was
generated at the endothelial surface the initial perturba-
tion was modeled focusing at the endothelial layer, with
the response of the epithelial component being subse-
quently driven by the output of the endothelial-inflam-
matory cell interactions. Rather than having a localized
insult with either infectious agents (simulating infection)
or sterile endothelial damage (simulating tissue trauma)
as was the case in the base endothelial/inflammatory cell
ABM, gut ischemia was modeled as a percentage of the
total endothelial surface rendered "ischemic," a state
defined in the rules for the endothelial cell agents as an
"oxy" level < 60. The affected endothelial cell agents were
randomly distributed across the endothelial surface. The
degree (or percentage affected) of the initial "ischemia"
was controlled with a slider in the Netlogo interface.
Therefore "Percentage Gut ischemia" (= "%Isch") repre-
sents the independent variable as initial perturbation for
this model. Other than the changes noted above, no other
Simulated Level of Occludin Expression Figure 9
Simulated Level of Occludin Expression. Graph dem-
onstrating the levels of simulated occludin expression in con-
trol, exogenous NO, Cytomix, Cytomix with NO scavenger, 
Cytomix with ethyl pyruvate and Cytomix with NAD+ at 12 
h, 24 h and 48 h. Compare with Figure 6 from Ref [24] and 
Figure 2 from Ref [25] (latter is extrapolated from Western 
blot analysis).
Screenshots of Bilayer Gut ABM Figure 10
Screenshots of Bilayer Gut ABM. Bilayer configuration of the gut ABM, following the structure for "hollow" organs 
described in the text. Figure 10a is the view of bilayer from endothelial surface. Red cubes represent endothelial cell agents, 
with spherical inflammatory cell agents seen just below. Inflammatory cell agents move in the plane immediately below the 
endothelial surface, and these interaction rules are derived from the Innate Immune response ABM from Ref. [6]. Figure 10b is 
the view of bilayer from epithelial surface. Pink cubes represent epithelial cell agent, governed by rules transferred from the 
EBABM. Impairment of TJ protein metabolism is shown by darkening of the color of the epithelial cell agent, with the epithelial 
cell agents eventually turning black and changing their shape to a "cone" when TJs have failed (see Figures 11, 14–16).Theoretical Biology and Medical Modelling 2008, 5:11 http://www.tbiomed.com/content/5/1/11
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changes to the rules of either the endothelial/inflamma-
tory ABM or the EBABM were made.
To address the issue of modeling the production of post-
ischemic, pro-inflammatory lymph, attention is focused
on linking the knowledge that has been acquired regard-
ing the characteristics of the substance, and relating this
information to the components of the organ ABM. The
known characteristics listed above are used to exclude
potential candidate-substances/actors from considera-
tion. Specifically, this group comprises any of the cellular
agents and any of the included cytokines. Therefore, the
search is limited to:
1) An as-of-yet unidentified compound linked to cellular
damage. An example of such a compound would be high-
mobility box protein 1 (HMGB-1), which to date has not
been looked for in post-ischemic mesenteric lymph. In
the organ ABM this variable is termed "cell-damage-
byproduct," and it is calculated as a function of total
endothelial damage with a set decay rate consistent with
that of other bioactive compounds associated with
inflammation.
2) A luminal compound that diffuses in response to TJ
barrier failure. This would correspond to potential
byproducts of gut bacterial metabolism, or bacterial tox-
ins, or other soluble aspects of the gut luminal environ-
ment that would leak into the gut tissue by virtue of the
loss of barrier function. This variable is represented by
"gut-leak," which is equal to the "solute" (from the
EBABM) that penetrates the failed barrier.
3) A down-stream metabolite of compounds generated by
the inflammatory process. These would most likely be
compounds generated by superoxide and NO reactions.
For purposes of these simulations, levels of NO will be
used as a proxy for this possible candidate.
Therefore, the goal of the organ ABM simulation runs will
be to examine the time course levels of these three values
and identify which one (if any) matches the reported time
course effects of the post-ischemic mesenteric lymph.
Organ ABM: simulations and results
The initial goal with the organ ABM simulations was to
determine the greatest non-lethal level for "Percentage
Ischemia" (%Isch). It should be noted again that the
name of this variable is descriptive for how it is imple-
mented in the ABM, and not intended to match quantita-
tively, per se, with measured ischemia in vivo. Rather
"%Isch" is representative of the initial conditions for the
simulation that will produce a pattern of simulation
behavior that matches that of the in vivo system [20]. A
parameter sweep of this value was performed, using a pre-
viously described method [5] with the goal of identifying
the greatest non-lethal level for %Isch. This value was
determined to be 35, and will be used as the initial condi-
tion for the subsequent organ ABM runs.
The initial experiments with the organ ABM examined the
effect of gut ischemia on TJ protein metabolism and the
consequent effect on epithelial barrier function. The pri-
mary purpose of these experiments was to confirm that
the epithelial agents' TJ metabolism and inflammatory
signaling rules, as transferred from the EBABM, retained
Gut ABM with %Isch = 35 at 4 and 18 h Figure 11
Gut ABM with %Isch = 35 at 4 and 18 h. Figure 11a is a graph that demonstrates the timecourses of Cellwall Occludin and 
Cytoplasmic Occludin over 18 hrs with an initial "%Isch" = 35. The Cellwall Occludin is shown in Red, the Cytoplasm Occludin 
is shown in Blue. Note that Cytoplasm Occludin has started to recover at ~12 h. The delay in recovery of the Cellwall Occlu-
din is due to the persistent effect of NO on Occludin localization via the NSF pathway. Figure 11b is the view of gut ABM from 
the epithelial surface at 4 hours. Note the darkened sections of the epithelial surface, denoting impaired TJ protein metabolism 
and localization. The areas near the center and right upper corner of the layer show the change in shape from "cube" to 
"cone," indicative of TJ failure. Figure 11c is the view of gut ABM from the epithelial surface at 18 hours. Note how there has 
been progression to generalized TJ barrier failure, with only the small area in the left lower corner still with some intact TJs.Theoretical Biology and Medical Modelling 2008, 5:11 http://www.tbiomed.com/content/5/1/11
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time course validity when the initiating stimuli were gen-
erated from endothelial/inflammatory cell interaction
instead of exogenously administered cytomix. Figure 11
demonstrate the behavior of the gut ABM with "%Isch" =
35. In Fig 11a occludin levels (as a representative TJ pro-
tein) decreased during an 18 h period post insult, and bar-
rier function can be seen disturbed at 4 and 18 h (Figs 11b
and 11c), consistent with that seen in the published liter-
ature [41,42].
The output from a representative run of the organ ABM
with %Isch = 35 is shown in Figure 12, where the time
courses for "cell-damage-byproduct" (black line), "gut-
leak" (blue line) and NO (red line) can be seen. The pro-
inflammatory properties of the post-ischemic mesenteric
lymph are noted to increase the most at 3 h and 6 h and
remain out to 24 h [35,46]. Examining the time courses
shown in Figure 12, the candidate compound that most
closely approximates the pattern identified in the litera-
ture is the "cell-damage-byproduct." As discussed above,
this possible source of the unknown compound in post-
ischemic mesenteric lymph is based on the recognition of
certain "late" pro-inflammatory mediators produced by
activated and damaged cells, HMGB-1 being the most
studied as a possible key mediator in the pathogenesis of
sepsis [47]. To date, there have been no studies examining
the production or presence of HMGB-1 in post-ischemic
mesenteric lymph. However, based on the information
generated by the organ ABM, and placed in the context of
the knowledge framework concerning the characteristics
of pro-inflammatory mesenteric lymph, we will make a
hypothesis that some "later" byproduct of damaged gut tis-
sue, rather than a diffused material or direct metabolite of
first-pass inflammatory mediators, is the responsible
compound in post-ischemic mesenteric lymph. It is recog-
nized that this is "guided speculation;" however, it also
demonstrates how the construction and use of models in
the ABM architecture is an evolving process that parallels
the development and refinement of conceptual models.
As will be seen in the next section, the next scale of biolog-
ical organization to be addressed in the ABM architecture
involves the extension and integration of this hypothesis.
Development of multi-organ ABM: the gut-pulmonary axis 
of inflammation
Organs do not exist in isolation; their mutually comple-
mentary functions interact to sustain the organism as a
whole. Unfortunately, disease states can lead to a break-
down of these interactions, causing a cascade effect as sin-
gle organ dysfunction can lead to multiple system failure.
Sepsis and MOF are characterized by a progressive break-
down in these interactions, leading to recognizable pat-
terns of linked organ failure [48]. Therefore the next scale
of biological organization represented in the multi-scale
ABM architecture is that of organ-organ interaction. The
gut-pulmonary axis of multiple organ failure
[22,36,40,46] is used as the initial example of organ-to-
organ crosstalk. This relationship is relatively well defined
pathophysiologically (though not completely, as indi-
cated by the uncertainty of the identity of the pro-inflam-
matory compound in post-ischemic mesenteric lymph)
and represents an example of multi-organ effects of dis-
seminated disordered inflammation. Disordered acute
inflammation of the lung is termed Acute Respiratory Dis-
tress Syndrome (ARDS), and is manifested primarily by
impaired endothelial and epithelial barrier function, lead-
ing to pulmonary edema. This leads to impaired oxygena-
tion of arterial blood, requiring support of the patient
with mechanical ventilation. While the comprehensive
pathogenesis of ARDS involves additional subsequent
issues related, to a great degree, to the consequences of
mechanical ventilation (specifically the effects of baro-
trauma and shear forces on the airways, and the persistent
propagation of inflammation that results), for purposes of
this initial demonstration only the initiating events asso-
ciated with the development of ARDS will be modeled.
Those events concern the production and release into the
mesenteric lymph by ischemic gut (resulting from shock)
of various pro-inflammatory mediators, and their effects
Timecourses for "Candidate" variables in Post-ischemic Gut  Lymph Figure 12
Timecourses for "Candidate" variables in Post-
ischemic Gut Lymph. Graph of the dynamics of three 
potential "candidates" for the yet unidentified pro-inflamma-
tory compound seen in post-ischemic mesenteric lymph. 
Note that the units of the three graphs have been adjusted to 
show their time-courses side-by-side; the emphasis is on the 
patterns of the timecourses rather than the absolute values. 
The "cell-damage-byproduct" graph best follows the 
reported characteristics of post-ischemic mesenteric lymph, 
with the greatest rises in pro-inflammatory activity at 3 and 6 
h, and persisting to 24 h. "NO" rises early enough for the 
pro-inflammatory effect at 3 and 6 h, but is not present at 24 
h. The "Gut-leak" is delayed in its rise, and therefore cannot 
account for activity seen at 3 and 6 h.Theoretical Biology and Medical Modelling 2008, 5:11 http://www.tbiomed.com/content/5/1/11
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both on circulating inflammatory cells and the pulmo-
nary endothelium as they circulate back to the lung via the
mesenteric lymph (as discussed above)[21,22,36,40,49,
50]. At this point, the hypothesis regarding the nature of
the pro-inflammatory mediator in the mesenteric lymph
is extended to the assumption that, for modeling pur-
poses, the levels of "cell-damage-byproduct" will be the
proxy for the unidentified compound that is produced in
the ischemic gut and circulated to the lung, leading to
inflammation of pulmonary endothelium.
Extension of gut ABM to pulmonary ABM
Thus far emphasis has been on the development of the gut
organ ABM, and in order to model gut-pulmonary interac-
tions it is necessary to develop a pulmonary ABM as well.
Drawing upon the endothelial-epithelial bilayer configu-
ration for a "hollow" organ, the pulmonary ABM utilizes
the same endothelial-inflammatory cell component as the
gut ABM, predicated on the relative homogeneity in struc-
ture and function of capillary endothelial cells (the blood
brain barrier being the notable exception). Furthermore,
pulmonary epithelial cells behave very similarly to gut
epithelial cells with respect to tight junction metabolism
and epithelial barrier function [51]. Therefore the pulmo-
nary epithelial agent layer also utilizes the same rules as
the gut ABM epithelial agents with respect to these proc-
esses. There is, however, a difference in function of the
intact epithelial barrier, and the consequence of its failure.
The functional consequence of the intact pulmonary epi-
thelial barrier is effective oxygenation of arterial blood
(expressed at the endothelial lumen) via diffusion from
the alveolar epithelial surface. Pulmonary barrier failure
manifests as increased egress of fluid from the endothelial
lumen into the alveolar space. The effect of pulmonary
diffusate "leak" is modeled to affect the transfer of alveo-
lar oxygen to the endothelial surface. Thus far the "oxy"
level in both the base endothelial-inflammatory cell ABM
and the gut ABM is set at 100 for all non-perturbed
endothelial cells, predicated upon the assumption of con-
stant adequate pulmonary function. Now, with the mod-
eling of inflammation that would affect the efficacy of
systemic oxygenation (i.e. the lung), the systemic oxygen-
ation may be altered with the consequence that progres-
sive pulmonary dysfunction would feed back to the
system as whole. Thus the influence of the pulmonary
inflammation with respect to decreased pulmonary epi-
thelial barrier function, leading to increased diffusate
"leak" into the alveolar space. This in turn leads to
impaired oxygenation into the endothelial lumen, which
is summed across the surface of the model to produce a
measure of systemic arterial oxygen content. This value
will now represent the baseline "oxy" level for all other
systemic endothelial agents.
Multi-organ ABM: construction
Following the development of both a gut ABM and a pul-
monary ABM, the next step is to connect them in a linked
model. The topology of this relationship consists of two
parallel bilayer planes, each bilayer representing one of
the organ ABMs (Figure 13). This is the gut-lung-axis
ABM. The Z-axis orientation of both bilayers is the same,
to allow conservation of the agent rules for equivalent
agent classes (i.e. endothelial-epithelial-lumen relation-
ships are consistent). The simulated blood flow continues
to be modeled by movement in the XY plane immediately
inferior to the endothelial surface. Blood flow between
organs is simulated by adding a "perfusion" variable.
"Perfusion" refers to the time-steps that a circulating cell
remains in one organ bed before being transferred to the
other organ bed. For purposes of the model, large caliber
blood vessels and the heart are treated as biologically inert
with respect to inflammation. Perfusion time in each
organ is simulated at approximately 6 minutes, account-
ing for the general slowing of cellular flow during move-
ment through the capillaries and venules. The activation
of adhesion molecules on the circulating cells and corre-
sponding endothelial cells leads to increased time in an
organ bed, or, in the case of adhering and migrating cells,
persistence in one organ bed. On leaving the organ bed,
Screenshot of Multi-Bilayer Gut-Lung Axis ABM Figure 13
Screenshot of Multi-Bilayer Gut-Lung Axis ABM. The 
multiple bilayer topology of the Gut-Lung ABM is seen here. 
Letter A labels the pulmonary bilayer, with Aqua cubes rep-
resenting pulmonary epithelial cell agents, Red cubes repre-
senting pulmonary endothelial cell agents, and below are 
spherical inflammatory cell agents. Letter B labels the gut 
bilayer, with a similar configuration, the only difference being 
that gut epithelial cell agents are Pink. Circulating inflamma-
tory cell agents move between these two bilayers in the 
fasion described in the text.Theoretical Biology and Medical Modelling 2008, 5:11 http://www.tbiomed.com/content/5/1/11
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movement from one capillary bed to the other is assumed
to take less than one time step (<3 min) as cells are trans-
ferred directly to a random position on the other organ's
endothelial surface at the end of their "perfusion" inter-
val. Similarly, the flow of mesenteric lymph is modeled
with a new command "gut-lung-lymph-flow" in which
the level of "cell-damage-byproduct" is transferred from
the gut ABM endothelial space to the lung ABM endothe-
lial space. There is no equivalent flow of "cell-damage-
byproduct" in the other direction, though the effect of the
lung ABM on baseline systemic oxygenation (as described
above) represents the connection in the direction from
the lung to the gut. The endothelial activating properties
of "cell-damage-byproduct" are modeled by having this
variable activate its adjacent pulmonary endothelial agent
in a manner similar to "endotoxin," i.e. increasing levels
of "endo-selectin" and "endo-integren" levels, and pro-
ducing platelet activating factor ("PAF") and "IL-8".
Multi-organ ABM: simulated interventions and results
Two clinical conditions were simulated to model organ-
organ crosstalk along the gut-pulmonary axis of inflam-
mation. The first has already been discussed at length: gut
ischemia resulting from shock, demonstrating the effect
that the gut has on the lung. The second will be a primary
pulmonary process that will in turn affect the gut: pneu-
monia. "Pneumonia" is modeled as in infectious insult to
the lung ABM using the same initial infectious insult rules
as for the base endothelial-inflammatory ABM [5,6].
Infectious agents are added in a localized fashion, and
damage endothelial cells, produce "endotoxin" when
killed and replicate if not suppressed. In the gut-lung-axis
ABM the resulting damage to the lung and increased sim-
ulated pulmonary edema impair systemic oxygenation,
and this leads to gut ischemia. Also, activation of inflam-
matory cell agents by the infectious agents potentiates
their pro-inflammatory behavior once they are in the gut
ABM endothelial surface. An example of simulated "pneu-
monia" is seen in Figure 14. Again, it should be noted that
the simulated conditions and interventions at the organ
level are admittedly abstract; it is not the intent of this
demonstration to simulate the complete complex patho-
physiology of pneumonia and sepsis. However, the
aspects of both pneumonia and sepsis that are simulated
do represent the central processes involved, and serve to
illustrate the capability of this modeling architecture to
represent the interactions, based on what is recognized in
the literature, between these two organ systems.
Figure 15 demonstrate the effects of mesenteric ischemia
on pulmonary barrier dysfunction. Note that the sub-
lethal "%Isch" has been dropped to 11 (Figure 15a and
15b), while the "%Isch" = 13 results in a lethal dynamic
(Figures 15c and 15d). As expected, the corresponding
lethality of mesenteric ischemia in the gut-lung ABM is
significantly increased as compared to the gut ABM alone,
dropping the sub-lethal "%Isch" from 35 for the gut ABM
to 11 for the gut-lung ABM. This results from the addition
of the lung ABM and its effect of decreasing the maximally
available "oxy" to non-perturbed endothelial agents via
the consequence of pulmonary epithelial barrier function
("pulm-edema"). The "survival space" of the system is
therefore greatly limited, and it may initially appear that
this model would be unsuited to examining the range of
dynamics of interest in the study of sepsis. However, it
should be noted that the high lethality of mesenteric
ischemia, which implies the presence of hemodynamic
shock, is "historically" correct. Shock states, prior to the
development of fluid resuscitation and respiratory sup-
port, were nearly universally fatal. This is the circumstance
that is being represented with the gut-lung ABM at this
point. If the goal is to simulate the clinical conditions
associated with sepsis and MOF, then it is necessary to
simulate the effects of organ support, to shift the "survival
space" to the right. Doing so reproduces the fact that sep-
sis and MOF are a "disease of the ICU," arising only after
the advances of resuscitative, surgical, antimicrobial and
organ-supportive care allowed the maintenance of
patients in situations where they previously would have
died. Therefore, sepsis and MOF can be thought of as a
previously unexplored behavior space of systemic inflam-
mation, one where the inflammatory system is function-
Simulated "Pneumonia" with effect on Gut Barrier Dysfunc- tion Figure 14
Simulated "Pneumonia" with effect on Gut Barrier 
Dysfunction. This panel shows a representative run of the 
Gut-Lung Axis ABM with "pneumonia" as the initial perturba-
tion. Letter A demonstrates the localized injury to the pul-
monary bilayer, Letter B demonstrates areas of the gut 
epithelial layer that are starting to have impaired TJ protein 
metabolism due to gut ischemia from decreased systemic 
oxygenation arising from pulmonary leak.Theoretical Biology and Medical Modelling 2008, 5:11 http://www.tbiomed.com/content/5/1/11
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ing beyond its evolutionarily defined design parameters
[5,6].
Therefore, to accomplish this goal, a very abstract means
of organ support is modeled in the form of "supplemen-
tary oxygen." This function increases the amount of "oxy"
that is able to be diffused through the pulmonary epithe-
lial barrier and therefore available as systemic oxygena-
tion. This is the qualitative equivalent of increasing the
fraction of inspired oxygen, and therefore alveolar oxygen,
Effect of Gut Ischemia on Pulmonary Barrier Dysfunction and Pulmonary Edema Figure 15
Effect of Gut Ischemia on Pulmonary Barrier Dysfunction and Pulmonary Edema. Figure 15a shows the dynamics 
of pulmonary occludin levels (as a proxy for pulmonary barrier dysfunction) in a representative run with a sub-lethal initial 
"%Isch" = 11 over a 72 hour run. Levels of both Cytoplasm Occludin and Cellwall Occludin nadir at ~24 hrs, then show gradual 
recovery as inflammation subsides. TJ protein levels continue to rise towards 72 hours. This pattern is consistent with that 
seen clinically in the recovery of pulmonary edema secondary to inflammatory causes. Figure 15b shows a screenshot for this 
representative run at the end of 72 hours, demonstrating a mostly recovered pulmonary epithelial surface. Figure 15c shows 
the dynamics of pulmonary occludin levels in a representative run with a lethal initial "%Isch" = 13. Level of both Cytoplasm 
Occludin and Cellwall Occludin are seen to drop consistent with progressive activation of pulmonary endothelium and produc-
tion of NO, leading to pulmonary TJ failure. This run is terminated at 24 because endothelial damage is nearly complete, as 
seen in the corresponding screenshot in Figure 15d. Figure 15d Letter A points to black cubes representing "dead" endothelial 
cell agents. These agents "die" owing to a decrease in the available maximal "oxy" level to below the threshold for generalized 
endothelial agent activation. The impaired systemic oxygenation due to pulmonary leak arises from pulmonary epithelial barrier 
failure. Letter B points to the only remaining intact pulmonary epithelial cell agents. Letter C points to the only remaining intact 
gut epithelial cell agents. Letter D points to the only remaining patches of surviving endothelial agents (red areas seen through 
the failed gut barrier).Theoretical Biology and Medical Modelling 2008, 5:11 http://www.tbiomed.com/content/5/1/11
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and therefore can increase the partial pressure of oxygen
diffused in the blood. It is qualitative in so much as there
is no attempt to reproduce the dynamics of gas exchange,
or the binding of hemoglobin to oxygen in the blood, or
the effects of redistributed ventilation-perfusion matching
in the lung as a result of hypoxia. This degree of detail is
beyond the scope of this initial demonstration model;
however the qualitative behavioral effects do show that
this type of support, even abstractly modeled, increases
the richness of the behavior of the model as a whole, and
can extend the examinable behavior space of the model to
situations that can approximate the effects of organ sup-
port in the ICU. The corresponding changes in outcome
with this type of simulated organ support can be seen in
Figure 16.
This sequence illustrates an important point in creating
translational models of disease states. The tendency may
be to attempt to model the pathological state being stud-
ied, i.e. creating a model of sepsis. However, it needs to be
remembered that pathological states result from transi-
tions from normal physiological behavior, and if the
intent of a model is to facilitate the eventual transition
from disease back to health, then "normal" mechanism
must be the basis of a translational model. The need to
capture transitions from one state to another takes on fur-
ther importance when the pathological state results, as
with sepsis, from medical/clinical interventions. There-
fore, the architecture of a modeling structure needs to be
flexible enough to accommodate the addition and inte-
gration of these factors, and it is hoped that the presented
modular structure of the ABM architecture demonstrates
this capability.
Discussion
The biomedical research community today faces a chal-
lenge that has paradoxically arisen from its own success:
as greater amounts of information become available at
increasingly finer levels of biological mechanism it
becomes progressively more difficult for individual
researchers to survey and integrate information effec-
tively, even within their own area of expertise. Though
technology, via tools like PubMED, the introduction of
new publication formats like open-access journals and the
Effect of Simulated Supplementary Oxygen on dynamics of simulated Pneumonia Figure 16
Effect of Simulated Supplementary Oxygen on dynamics of simulated Pneumonia. Figure 16a demonstrates the 
dynamics of pulmonary Cytoplasm and Cellwall occludin in a representative run with an initial "%Isch" = 15, and the addition of 
simulated organ support in the form of "Supplementary Oxygen" at 50%. The effect of "Supplementary Oxygen" is additive to 
the level of "oxy" generated by the lung ABM and distributed to the endothelial surface. The initial drop of the pulmonary 
Occludins is consistent with inflammatory effects of post-ischemic mesenteric lymph. The effect of the "Supplementary Oxy-
gen" is to blunt the effect of the resulting pulmonary edema, and it keeps the "oxy" level above the threshold ischemic level for 
activation of the generalized endothelial cell agent population. As a result the endothelial surface if maintained through the 
period of most intense inflammation, and allows the epithelial cells to begin recovery of their TJs (see Letter A in Figure 16a). 
The stabilization and initiation of recovery of pulmonary epithelial TJs at 72 hours is consistent with the clinical time course of 
adult respiratory distress syndrome due to an episode of shock. Figure 16b is a concurrent screenshot of the representative 
run. Letter A demonstrates the intact endothelial agent layer due to "Supplementary Oxygen" support (compare with Figure 
15c, Letter A). Letter B demonstrates the recovering pulmonary epithelial cell agents. Letter C demonstrates intact and recov-
ering gut epithelial.Theoretical Biology and Medical Modelling 2008, 5:11 http://www.tbiomed.com/content/5/1/11
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development of a whole slew of bioinformatics tools, has
aided the distribution and availability of biomedical
information, it still falls upon the individual researcher to
concatenate that information into a conceptual model
that represents it. These mental models guide the direc-
tion of their individual research and, in aggregate, the
form the components of the evolving structure of commu-
nity knowledge. However, the formal expression of men-
tal models remains poorly defined, leading to limitations
in the ability to share, critique and evolve the knowledge
represented in these conceptual models, particularly
across disciplines. As a result it is increasingly difficult for
both the individual researcher, and the community as a
whole, to "know what it knows."
These limitations can be overcome by developing meth-
ods of formal dynamic knowledge representation to allow
researchers to express and communicate their mental
models more effectively. Furthermore, in order to be able
to "see" the consequences of a particular hypothesis-struc-
ture/mental model, the formally represented knowledge
should be moved from a static depiction to a dynamic
model in which the mechanistic consequences of each
hypothesis can be observed and evaluated. In addition, as
seen in the example of modeling the pro-inflammatory
aspects of the post-ischemic mesenteric lymph, a method
of formal dynamic knowledge representation also allows
researchers to propose alternative solutions and generate
hypotheses in the process of creating a model, so long as
these hypotheses and assumptions are made explicit. This is
necessary in any attempt to formalize the representation
of conceptual models, as it will always be necessary to
deal with the issue of incomplete knowledge. These mod-
els can aid in the scientific process by providing a trans-
parent framework for this type of speculation, which can
then be used as "jumping off" points for the planning and
design of further wet lab experiments and measurements.
I propose that ABM is a method well suited to fulfilling
the goals of dynamic knowledge representation.
This paper has presented a series of ABMs that are
intended to introduce a multi-scale architecture that has
the potential to serve as an overall unifying structure for
representing biomedical knowledge. The "encapsulation"
represented by the agent-based paradigm does not pre-
clude the development of equation based or stochastic
models; rather the modular, encapsulating structure is
agnostic to the nature of the agent rule systems, and
agnostic to the method of linkage to the various compo-
nents. This is consistent with the "functional unit repre-
sentation method" (FURM) concept developed by Hunt
[52,53]) in which computational models of biological
systems would be assemblies of methodologically agnos-
tic components. To state this in multi-scalar terms, such a
architecture would allow each level of organization to be
modeled with a methodology, or multiple methodolo-
gies, most suited to its particular characteristics [54,55]).
As a result there is an expectation that these assembled-
models would be hybrids of different modeling tech-
niques [2,14]).
The ABMs presented herein represent admittedly abstract
representations of mechanistic hypotheses, but this need
not be the case. Equations "encapsulate" knowledge as
well, by providing mathematical abstractions of behavior
that none-the-less must actually be implemented by some
biological object. The extensive work on the mathematical
characterization of intracellular processes in the systems
biology field can form the basis of cell-level agent rules. In
particular, the encapsulation offered by the ABM para-
digm offers a method of meeting current challenges in the
application of mathematical modeling techniques, such
as parallel implementation of stochastic modeling with
Gillespie algorithms, to reproduce population behavior
and transcend biological scales of organization. The com-
plexity and detail of these models is constrained only by
the scope of that knowledge, and the ability to compute
subsequently expressed rules. The former is the subject of
the ongoing scientific process aimed at identifying mech-
anisms; the latter is the being addressed by a concurrent
research community that seems to follow, at worst, the
exponential progress represented by Moore's Law.
Currently ABMs are severely limited by their computa-
tional requirements. For instance, the Netlogo models
presented here are limited to a few thousand agents run-
ning abstract rules on a high-end desktop machine (spe-
cifically a Macintosh MacPro Dual-Core Intel 3.0 GHz
Xeon with 8 MB of RAM), with the result that a run of 7
days simulated time in the gut-lung axis ABM takes
approximately 30 minutes. While scaling up pure ABM
models is at this time not feasible, there is promise on the
horizon. Advances in supercomputing have moved into
implementation of distributed systems, including grid
computing, massively parallel machines such as IBM's
Blue Gene P, and the use of novel chip technologies such
as the Cell© processor (as found in Sony's PS3) and graph-
ical processing units (GPUs). However, despite the com-
putational promise of these hardware platforms, there are
still significant hurdles to the efficient implementation of
ABM on these distributed systems. Central to these is the
latency between intra-processor computational speed and
that of node-to-node inter-processor speed. One
approach is to improve the efficiency of the computa-
tional demands, such as reducing the number of agents
that need to be treated individually via "dynamic agent
compression" [56] or streamlining the execution of a
computationally expensive step, such as a Gillespie algo-
rithm [57]. Another approach is to develop novel load-
balancing algorithms, ironically inspired by biologicalTheoretical Biology and Medical Modelling 2008, 5:11 http://www.tbiomed.com/content/5/1/11
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systems, that offer the promise of finding a solution to the
challenge of distributing an ABM across a distributed sys-
tem [58-60]. That a full-scale ABM implementation is not
possible at this time does not obviate the need to develop
and communicate the potential framework that is concep-
tually robust and allow the evolution of knowledge repre-
sented in a computable form.
In short, the agent-based paradigm, with its defining char-
acteristics of encapsulation, modularity and parallelism,
can provide an over-arching design architecture for the
computational representation of biological systems. The
examples presented herein are intended to be an introduc-
tion to this framework. For example, the detail of the
molecular events can be represented at a finer grained
level using ordinary differential equations, Gillespie-type
algorithms or even particle-based signaling models. Cell
behavior can be expressed as differential equation models
derived from more detailed kinetic knowledge of their
response curves. The physiological functions of individual
organs can be represented using detailed physical system
models detailing shear forces, stress response curves and
contractility patterns. Every encapsulated object, at any
hierarchy, can be represented in exhaustive detail using
mathematical tools. However, two primary question exist:
1) is it even possible to exhaust the level of detail achiev-
able to a pure reductionist's satisfaction? And 2) is it even
necessary for the goal of conceptual model verification
and representing knowledge? The modular, multi-scale
agent-based architecture presented herein does not seek to
answer those particular questions, but does hope to func-
tion as a seeming paradoxical solution to both questions
by: 1) offering the opportunity to dig as deeply and with
as much detail as desired, but also 2) to allow knowledge
to be expressed effectively and usefully in the qualitative
fashion that most researchers use to establish their con-
ceptual models. This latter point cannot be over-empha-
sized, as ultimately the defining aspect of science is
skepticism, the Popperian goal of hypothesis nullifica-
tion.
Availability
The software used to create this model, Netlogo [28], is
freely available for download at:http://ccl.northwest
ern.edu/netlogo/. Netlogo is a self-contained modeling
toolkit, and is available for Windows, Macintosh and
Linux. The Netlogo version of the innate immune
response/endothelial model can be accessed at http://bio
netgen.org/SCAI-wiki/index.php/Main_Page. The EBABM
itself is available for download at: http://ccl.northwest
ern.edu/netlogo/models/
communitShock2004_Gut_Epithelial_Barrier. The
endothelial/inflammatory cell model can be downloaded
at: http://ccl.northwestern.edu/netlogo/models/commu-
nity/Innate%20Immune%20Response. The Gut ABM and
the Gut-Lung = Axis are available for download at:
http:bio netgen.org/SCAI-wiki/index.php/Gary_An.
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